Novel Drug Modalities DMPK Enabling Platforms
WuXi AppTec DMPK has extensive experience and established pharmacokinetics evaluation systems for ADC, PDC, Oligo, Peptide, mRNA, Covalent Drugs, Proteolysis Targeting Chimera (PROTAC*) pharmacokinetic studies based on the in vivo and in vitro pharmacokinetic studies platform – to help drug developers quickly advance their drug development projects.
-
Overview
-
Novel Drug Modalities
-
Related Resources
-
Related Services
Novel Drug Modalities
Overview
Our dedicated R&D team has summarized pharmacokinetic research strategies and established comprehensive evaluation solution from in vitro to in vivo for different novel drug modalities. The team consists of experts in different fields covering in vitro and in vivo ADME, metabolite identification, QWBA and radiolabeled mass balance, and bioanalysis.
We have collaborated with pharmaceutical and biotech companies focusing on new drug modalities. We have successfully supported thousands of projects and conducted extensive testing on tens of thousands of drug molecules, including peptides, antibodies, oligonucleotides, PROTACs, ADCs, PDCs, mRNA, Covalent Drugs, and etc.
Learn More
Novel Drug Modalities
-
PROTAC DMPK Services
Based on the pharmacokinetics evaluation systems for PROTAC molecules, WuXi AppTec DMPK has supported the screening of tens of thousands of PROTAC molecules and the IND applications of dozens of PROTAC molecules. In this process, we have formed a unique methodology for PROTAC pharmacokinetic studies - aimed at helping drug developers rapidly advance their PROTAC drug development projects.
-
ADC (Antibody-Drug Conjugate) DMPK Services
Based on the ADC integrated platform, WuXi AppTec DMPK has supported more than 200 ADCs for screening and more than 20 ADCs for IND filing. Throughout this process, we have accumulated extensive experience and can propose a specific DMPK strategy for each ADC project, which can effectively shorten the ADC development cycle.
-
Oligonucleotide Drugs DMPK Services
We have helped more than 70 global clients successfully screen and evaluate oligonucleotide pipelines, and have enabled dozens of oligonucleotide molecules’ IND applications, including ASO, siRNA, miRNA, and more. We not only have extensive experience in studying oligonucleotides but also have developed a specific methodology for the pharmacokinetic study of oligonucleotide drugs.
-
Peptide-Drug Conjugate (PDC) DMPK Services
Based on the characteristics of PDCs, the development strategy and assay condition of PDCs are customized according to our experience. WuXi AppTec DMPK has successfully supported more than 20 clients on PDC projects, including some IND-enabling studies.
-
Peptide Drugs DMPK Services
Based on the peptide integrated platform, WuXi AppTec DMPK has supported more than 140 global clients on peptide projects, including the screening of tens of thousands of peptide molecules and the IND applications of dozens of peptide molecules.
-
mRNA-Based Vaccines and Therapeutics Drugs DMPK Services
To facilitate the research and development of mRNA-based vaccines and therapeutics, WuXi AppTec DMPK has established an integrated bioanalytical platform. This platform includes qPCR, branched DNA (bDNA), ligand binding assays (LBA), liquid chromatography-mass spectrometry (LC-MS), and flow cytometry, enabling quantitative and semi-quantitative analysis of mRNA.
-
Covalent Drugs DMPK Services
The mechanism of covalent drugs is different from that of conventional small molecule drugs, which may bring corresponding challenges to the ADME studies, such as distribution and elimination studies. WuXi AppTec DMPK has established ADME platforms specially for covalent drugs. Up to now, WuXi AppTec DMPK has successfully supported nearly 100 covalent drug projects for clients and has successfully pushed many covalent drugs into clinical trials.
Upcoming Events
Related Resources
-
Evaluating Oral Peptides' Gastrointestinal Absorption: Methods and Applications
ArticlesAug 28, 2025Learn More
-
Advancing Novel Therapeutics with Innovative DMPK Strategies in Metabolism and Bioanalysis
WebinarsAug 22, 2025Learn More -
Optimizing Liposomes/LNPs: From Lipid Solvent Screening to Formulation Stability in PK Studies
ArticlesAug 22, 2025Learn More -
An Efficient and Environmental Friendly Method for the Determination of Nucleoside Phosphate Compounds by Using LC-MS/MS
PostersAug 01, 2025Learn More -
Bioanalytical Strategy for Payload-Related Species of Antibody Drug Conjugates (ADCs) with LC-MS
PostersAug 01, 2025Learn More -
Antibody-Drug Conjugate (ADC) R&D Innovations and In Vitro ADME Research Considerations
ArticlesJul 24, 2025Learn More -
Solving the Peptide Puzzle: Strategies for Smarter Development
WebinarsJul 24, 2025Learn More -
An Integrated Radiolabeling and ADME Platform for Peptide Drugs
WebinarsJul 17, 2025Learn More -
mRNA Vaccines and Therapeutics: Advances in Modification, Delivery, Applications, and Analytical Strategies
ArticlesJul 17, 2025Learn More -
Optimization of Sample Pretreatment Methods for the Determination of an Oligonucleotide by Using LC-MS/MS
PostersJul 17, 2025Learn More -
A Robust LC-MS/MS Method for the Detection of Covalent Drugs in Mouse Blood
PostersJul 10, 2025Learn More -
An Ultra High-Throughput Method for 13C6-Fructose-6-Phosphate in Cells Using Acoustic Ejection Mass Spectrometry (AEMS)
PostersJul 04, 2025Learn More -
A Novel Validated LC-MS/MS Method for the Determination of Survodutide in Mouse Liver
PostersJul 04, 2025Learn More -
Exploring T-Cell Engagers (TCEs): Mechanism, Challenges, and Pharmacokinetic Considerations
ArticlesJul 04, 2025Learn More -
In Vitro Metabolism Methods for Oligonucleotides
White PapersJun 20, 2025Learn More -
How to Analyze and Separate Oligonucleotides and Active Metabolites Using LC-MS/MS
ArticlesJun 20, 2025Learn More -
Sample Chapter: Proteolysis-Targeting Chimeras (PROTACs) from Drug Metabolism and Pharmacokinetics: Frontiers, Strategies, and Applications
PublicationsJun 06, 2025Learn More -
Advancing In Vitro Metabolic Models and Metabolite Identification for Oligonucleotide Therapeutics
WebinarsJun 05, 2025Learn More -
Unlocking Reliable In Vitro Metabolic Models for Oligonucleotide Therapeutics with the Latest Publication on DMD
BlogsMay 28, 2025Learn More -
8 Commonly Used ADC Payloads and Their ADME and DDI Properties
ArticlesMay 22, 2025Learn More -
Discovery and Evaluation of Pyrazolo[3,4‑d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor
PublicationsMay 15, 2025Learn More -
Cyclic Peptides: FDA-Approved Drugs and Their Oral Bioavailability and Metabolic Stability Tactics
ArticlesMay 08, 2025Learn More -
Comparative Metabolism of a GalNAc-Conjugated siRNA, Inclisiran, Among Various In Vitro Systems and Correlations with In Vivo Metabolism in Rats
PublicationsMay 08, 2025Learn More -
2024 FDA-Approved Drug Highlights: Overview of Human Pharmacokinetics and DDI Profiles
ArticlesApr 29, 2025Learn More -
Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by High-Resolution Mass Spectrometry and Multiple Data Mining Tools
PublicationsApr 28, 2025Learn More -
Immunogenicity Testing: Definition, Guidelines, and Anti-Drug Antibody Detection
ArticlesApr 25, 2025Learn More -
An Efficient Bioanalytical Method for mRNA Drug in Mouse Blood and Tissue Samples
PostersApr 17, 2025Learn More -
Covalent Drugs DMPK Services
BrochuresApr 10, 2025Learn More -
Enhancing Permeability Through Exposed Polar Surface Area (EPSA) for Beyond Rule of Five (bRo5) Drug Candidates
ArticlesApr 10, 2025Learn More -
FAQs on Oligonucleotide DMPK Studies Stability, Distribution, Administration, and Bioanalysis
BlogsApr 03, 2025Learn More -
Unlocking Precision in Peptide Metabolite Identification for Next-Gen Drug Development
ArticlesMar 19, 2025Learn More -
Marketed Bispecific Antibodies and Their Pharmacokinetic Characteristics
ArticlesMar 14, 2025Learn More -
Optimization of the LLOQ for Exatecan, a Widely-Used Antibody Drug Conjugate (ADC) Payload
PostersMar 12, 2025Learn More -
Bioanalytical Strategy for Quantitative Conjugated Payloads of Antibody-Drug Conjugates (ADCs) with Cleavable Linker
PostersMar 12, 2025Learn More -
Streamlining the Bioanalysis of Antibody-Drug Conjugates (ADCs): Simultaneous Determination of Total Antibodies and Conjugated Payloads
ArticlesMar 04, 2025Learn More -
Navigating Complexities in Oligonucleotides: DMPK Strategies and CNS-Targeting Solutions
WebinarsFeb 20, 2025Learn More -
Antibody-Drug Conjugate (ADC) Preclinical PK/PD Study Strategies and Practices
ArticlesFeb 19, 2025Learn More -
Development of a Rapid, High Throughput Quantitative Bioanalysis Method for Conjugated Payloads of Protease-Cleavable Antibody-Drug Conjugate (ADC) in Rat Serum Using Automated Immuno-Capture Based UPLC-MS/MS
PostersFeb 06, 2025Learn More -
Comprehensive Mass Spectrometry Based Bioanalysis Strategy for Antibody-Drug Conjugate Therapeutics
PostersJan 30, 2025Learn More -
Unlocking High-Throughput Bioanalysis of Covalent Drugs with Intact Protein, DSF, and Peptide Mapping Techniques
ArticlesJan 20, 2025Learn More -
Methodologies and Strategies for ADC Biotransformation Studies
WebinarsJan 15, 2025Learn More -
Webinar Q and A | Optimizing DMPK Strategy for Peptide Drugs
BlogsJan 13, 2025Learn More -
Methods and Strategies for In Vitro Metabolism Studies of Oligonucleotides
ArticlesJan 08, 2025Learn More -
Exploring Our Latest Publication on Bioanalysis: Review on the Bioanalysis of Non-Virus-Based Gene Therapeutics
BlogsDec 30, 2024Learn More -
WuXi AppTec DMPK: Your Trustworthy Partner
VideosDec 27, 2024Learn More -
Advancing Antibody-Drug Conjugates (ADCs) with Novel Payloads and Their DMPK Considerations
ArticlesDec 10, 2024Learn More -
Successful Prediction of Oral Pharmacokinetics of the KRAS G12C Inhibitor MRTX-849 in Humans Using PBPK Modeling
PostersDec 03, 2024Learn More -
Metabolite Identification in Peptide Drugs and Its Challenges
ArticlesDec 02, 2024Learn More -
Optimizing DMPK Strategy for Peptide Drugs
WebinarsNov 21, 2024Learn More -
Spotlight on the DMPK and Bioanalysis Strategy of Antibody Oligonucleotide Conjugates (AOCs)
ArticlesNov 21, 2024Learn More
Stay Connected
Keep up with the latest news and insights.
